About: Satavaptan     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatDiuretics, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon
http://dbpedia.demo.openlinksw.com/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FSatavaptan&invfp=IFP_OFF&sas=SAME_AS_OFF&graph=http%3A%2F%2Fdbpedia.org&graph=http%3A%2F%2Fdbpedia.org

Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009.

AttributesValues
rdf:type
rdfs:label
  • Satavaptan (it)
  • Satavaptan (en)
rdfs:comment
  • Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009. (en)
  • Satavaptan (Nome in codice dello sviluppo SR121463, ex marchio provvisorio Aquilda) è un antagonista del recettore della vasopressina-2 che è stato scoperto dalla Sanofi-Aventis ed era in fase di sviluppo per il trattamento dell'iponatremia. È stato anche studiato per il trattamento dell'ascite. Lo sviluppo è stato interrotto nel 2009. (it)
foaf:depiction
  • http://commons.wikimedia.org/wiki/Special:FilePath/Satavaptan_structure.svg
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
sameAs
dbp:wikiPageUsesTemplate
thumbnail
ATC prefix
  • none (en)
c
CAS number
ChemSpiderID
H
IUPAC name
  • N--4-{[-5'-ethoxy-4--2'-oxospiro[cyclohexane-1,3'-indol]-1'-yl]sulfonyl}-3-methoxybenzamide (en)
n
O
PubChem
s
SMILES
  • C1COCCN1CCO[C@H]2CC[C@]3c4ccccc4NSc5cccCNCC (en)
StdInChI
StdInChIKey
  • QKXJWFOKVQWEDZ-VCCCEUOBSA-N (en)
UNII
  • AJS8S3P31H (en)
Verifiedfields
  • changed (en)
verifiedrevid
Watchedfields
  • changed (en)
width
has abstract
  • Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009. (en)
  • Satavaptan (Nome in codice dello sviluppo SR121463, ex marchio provvisorio Aquilda) è un antagonista del recettore della vasopressina-2 che è stato scoperto dalla Sanofi-Aventis ed era in fase di sviluppo per il trattamento dell'iponatremia. È stato anche studiato per il trattamento dell'ascite. Lo sviluppo è stato interrotto nel 2009. (it)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
CAS number
  • 185913-78-4
FDA UNII code
  • AJS8S3P31H
PubChem
  • 9810773
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 52 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software